Please ensure Javascript is enabled for purposes of website accessibility

Winners and Losers of Europe’s Big Cancer Meeting

By Brian Orelli, PhD – Updated Oct 2, 2019 at 4:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Unfortunately, there were more of the latter.

The European Society for Medical Oncology (ESMO) meeting, which wrapped up on Tuesday, featured presentations from a few smaller companies that saw their stock prices move substantially after the meeting.

Company Return Since Start of Meeting
Seattle Genetics (SGEN -0.42%) 11.3%
Immunomedics (IMMU) (7.7%)
G1 Therapeutics (GTHX 3.76%) (32.1%)
Mirati Therapeutics (MRTX 2.89%) (14.4%)

Data source: YCharts.

Hitting a double

Seattle Genetics wowed investors with a pair of clinical trials.

Tucatinib helped 52.2% of late-stage colorectal cancer patients when combined with Roche's Herceptin. The results should give investors confidence in a late-stage study called Her2climb, testing tucatinib in patients with metastatic breast cancer, which is expected to read out later this year.

Enfortumab vedotin (EV), which is up for Food and Drug Administration review in patients with late-stage urothelial cancer, also appears to help previously untreated patients with the same type of cancer when combined with Merck's (MRK 0.64%) Keytruda. A solid 71% of patients responded to the combination.

Tough competition

Immunomedics' sacituzumab govitecan (SG) produced a response in 29% of patients with late-stage urothelial cancer. That shouldn't be compared to Seattle Genetics' 71% response rate for EV since these are late-stage patients who should be harder to treat. Unfortunately for Immunomedics, Seattle Genetics' late-stage patient data, currently under review by the FDA, showed 44% of patients responded to EV.

Immunomedics also announced a delay in plans to resubmit its application for SG as a treatment for breast cancer that was rejected earlier this year. Instead of resubmitting the application early in the fourth quarter, Immunomedics now plans to file in late November or early December. A couple of months' delay shouldn't be that big a deal -- especially if it ultimately increases the likelihood of approval -- but short-minded investors might have been selling on the news.

Doctor sitting at a table with a patient.

Image source: Getty Images.

Known knowns and known unknowns

G1 Therapeutics disclosed in June that its phase 2 trial of trilaciclib helped patients with metastatic triple-negative breast cancer live longer. The data presented at ESMO put some numbers to the results, showing trilaciclib plus chemotherapy helped patients live a median of 20.1 months compared to 12.6 months for patients taking chemotherapy alone.

Maybe investors were expecting a larger difference, but more likely, the report ended up being a sell-the-news event, especially when combined with a second clinical trial presentation at ESMO for one of G1's other pipeline drugs that was rather disappointing.

An early-stage study of G1T48 in a different type of breast cancer showed only 1 of the 19 evaluable patients experienced a partial response. Granted, these are late-stage patients who have failed multiple treatments, but a 5.3% response rate is still rather poor.

Competition fails

Mirati Therapeutics didn't present any significant data at ESMO this year for its KRAS inhibitor MRTX849, but its shares fell because its competitor Amgen (AMGN 0.12%) presented miserable data for its competing KRAS inhibitor AMG 510. In an early-stage clinical trial, only 1 of the 12 colon cancer patients treated with the highest dose had a partial response to AMG 510.

MRTX849 might be different enough to work, but the disappointment in colon cancer is likely a class effect, since Amgen has shown AMG 510 works well in lung cancer, where 54% of patients responded.

Best buy?

When investing in biotechs, it's usually better to jump in late after seeing good data than to try to catch the bottom after disappointing news, making Seattle Genetics the clear winner of the group.

If you're dead set on investing in something on sale, the move in G1 Therapeutics looks overdone. But with a market cap that's still more than $850 million and no drugs on the market, it's hard to argue that G1 is a great value, even after the post-ESMO fall.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Seattle Genetics. The Motley Fool recommends Amgen and Immunomedics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$123.44 (-0.42%) $0.52
Immunomedics Stock Quote
Mirati Therapeutics Stock Quote
Mirati Therapeutics
$98.62 (2.89%) $2.77
G1 Therapeutics, Inc. Stock Quote
G1 Therapeutics, Inc.
$6.35 (3.76%) $0.23
Merck & Co. Stock Quote
Merck & Co.
$107.50 (0.64%) $0.68
Amgen Stock Quote
$283.74 (0.12%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.